Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Director Jim Delshad Purchases 5,000 Shares of Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Director Jim Delshad bought 5,000 shares of the business’s stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $7.22 per share, for a total transaction of $36,100.00. Following the completion of the purchase, the director now owns 55,310 shares in the company, valued at approximately $399,338.20. This trade represents a 9.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Jim Delshad also recently made the following trade(s):

• On Wednesday, March 26th, Jim Delshad bought 50 shares of Neonc Technologies stock. The shares were purchased at an average cost of $16.05 per share, for a total transaction of $802.50.
• On Thursday, April 17th, Jim Delshad purchased 50 shares of Neonc Technologies stock. The shares were bought at an average price of $6.92 per share, for a total transaction of $346.00.

Neonc Technologies Stock Performance

Neonc Technologies stock opened at $7.43 on Tuesday. Neonc Technologies Holdings, Inc. has a 12 month low of $4.11 and a 12 month high of $25.00.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings data on Friday, May 9th. The company reported ($2.10) earnings per share (EPS) for the quarter. The company had revenue of $0.04 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Neonc Technologies stock. Royal Bank of Canada purchased a new stake in shares of Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,525 shares of the company’s stock, valued at approximately $247,000.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing.